Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01732861 · ClinicalTrials.gov registry record · Phase 1

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

A Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
11
Study locations

NCT01732861 is a Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell that has completed, run by Celgene. The registered enrollment target is 20 participants, below the 489-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01732861, a Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
11
Study locations

Study Summary

This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).

Conditions Studied

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

  • DRUG Lenalidomide
  • DRUG CC-292

Study Locations (11)

Other

  • Universitatsklinik fur Innere Medizin - Innsbruck
  • AKh Linz - Linz
  • Universitatsklinik der PMU - Salzburg
  • Allgemeines Krankenhaus Wien - Vienna
  • Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie - Vienna

Alabama

  • Clearview Cancer Institute Oncology Specialties, P.C - Huntsville

Indiana

  • Horizon Oncology Center - Lafayette

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Mount Sinai School of Medicine - New York

Tennessee

  • The West Clinic - Memphis

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-12-28
Est. Completion 2019-01-23
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01732861

The ClinicalTrials.gov registry entry for NCT01732861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (96% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia, Lymphocytic, Chronic, B-Cell appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.

NCT01732861 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, Indiana.

Frequently Asked Questions

What is clinical trial NCT01732861 about?

NCT01732861 is a clinical study titled "Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma". This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 an...

What is the current status of trial NCT01732861?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-12-28. Estimated completion is 2019-01-23.

What conditions does trial NCT01732861 study?

This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic, B-Cell.

What interventions are being tested in trial NCT01732861?

The interventions under investigation include: Lenalidomide (DRUG), CC-292 (DRUG).

Who is sponsoring clinical trial NCT01732861?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01732861 being conducted?

This trial has 11 study locations across Alabama, Indiana, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia, Lymphocytic, Chronic, B-Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia, Lymphocytic, Chronic, B-Cell

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.